US International Development Finance Corporation has committed a long-term loan of up to USD 20 million to Panacea Biotec. The funds will help expand the manufacturing capacity for drug substance antigens used in its hexavalent vaccine EasySix, aimed at meeting future demand from UN agencies and public health organisations.
Disclaimer : Mymoneytimes implements extreme caution and care in collecting data before publication. Mymoneytimes does not liable for the adequacy, accuracy or completeness of any given information. Hence we are not liable for any kind of direct or indirect loss caused by the use of such information.